With trastuzumab biosimilars expected on the US market soon for HER2-positive breast cancer, an advocacy organization for patients with breast cancer said recently that it wants to provide education about the potential of the medicines to lower costs and provide more treatment options.
With trastuzumab biosimilars expected on the US market soon for HER2-positive breast cancer, an advocacy organization for patients with breast cancer said recently that it wants to provide education about the potential of the medicines to lower costs and provide more treatment options.
Trastuzumab attaches to the HER2 protein on the surface of the cancer cell, slowing or stopping the cancer cell from growing. In the US market, patents on Roche’s Herceptin, the originator trastuzumab, are expiring this year, clearing the way for competitors.
Biosimilars of trastuzumab have already entered the European market, and in the United States, 5 biosimilars (Ogivri, Kanjinti, Herzuma, Ontruzant, and Trazimera) have been FDA approved, though none are yet available to patients.
“The introduction of biosimilars is an important step in increasing options for treating HER2-positive breast cancers, which account for about 25% of all breast cancers. As patient advocates, we are working to ensure that patients are educated about biosimilars and can feel comforted that they are FDA approved and just as safe and effective as the original biologic drug,” said Paula Schneider, chief executive officer of Susan G. Komen, in a statement.
Susan G. Komen said there are 4 things it wants patients to know about biosimilars:
Breast cancer groups are also preparing for the introduction of trastuzumab biosimilars in Canada, where biosimilars have been available since 2009. Health Canada approved its first trastuzumab biosimilar, Mylan and Biocon’s Ogivri, in May.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Filgrastim Biosimilars in Europe: 15 Years of Real-World Evidence for Zarxio
March 13th 2024A review looking back at the last 15 years of experience with the first filgrastim biosimilar (Zarxio) provides a detailed overview on how filgrastim biosimilars came to be and the evidence behind why oncologists have come to accept them as standard practice.